ORION CORPORATION STOCK EXCHANGE RELEASE 22 OCTOBER 2014 at 6.25 p.m. EEST Composition of the Nomination Committee of Orion Corporation The Board of Directors of Orion Corporation has elected the following persons to the Nomination Committee of the company: Kari Jussi Aho Matti Kavetvuo Timo Ritakallio Seppo Salonen Hannu Syrjänen Jukka Ylppö Matti Kavetvuo was elected Chairman of the Committee. The Committee prepares and presents a recommendation to the Board of Directors for the proposal to the Annual General Meeting concerning the composition of the Board. The essentials of the working order of the Nomination Committee and a description of the election process of its members are provided at http://www.orion.fi/en/Orion-group/corporate-governance/board-of- directors/board-committees/, a page in the Corporate Governance section of the Orion Group internet website. Orion Corporation Timo Lappalainen Olli Huotari President and CEO SVP, Corporate Functions Contact person: Timo Lappalainen tel. +358 10 426 3692 Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo, Finland Homepage: www.orion.fi Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs. Orion's net sales in 2013 amounted to EUR 1,007 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki. [HUG#1864797]